Good MorningEquity markets tried to advance for the 5th day on Thursday, but the gains were slim, the index closed virtually flat, and the peak of the move may have been reached. The PCE Price Index for July came in hotter than expected and shows consumer-level inflation is accelerating. The data increased the fear of another Fed rate hike, although the market still believes the committee is already done. The odds of another hike are less than 50/50, as indicated by the CME FedWatch Tool, and softened following the release.
The S&P 500 advanced solidly for the week, and an interesting setup is developing. The market could continue higher but will have to break critical resistance levels. Those levels coincide with the summer peak and, if not broken, may produce a double top of another bearish pattern in the index. In that scenario, the market could fall 5% to 10% from current levels before hitting firm support, and there is additional risk. The next FOMC meeting is less than 3 weeks away, and another inflation report is due before then. Featured: Incredible Investment Opportunity - Get In On the Ground Floor (Thumbzup) 
|
Markets | | |
While the concept of artificial intelligence (AI) has been around for decades, 2024 was truly the breakout year and tipping point, making it accessible for anyone and everyone with internet access. The viral popularity of ChatGPT and generative AI has spread adoption like wildfire. While many arti... Read the Full Story |
|
From Our PartnersThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return. | | | | Get the Details Here >>> |
|
Stocks | | |
Cybersecurity stocks are down hard compared to last year, but not because the industry isn't hot.
The problem was valuation, fears of slowing growth and threats of a looming recession. According to the Q2 reporting season, growth is slowing but still robust and above consensus. In addition,... Read the Full Story |
|
Stocks | | |
Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and Amgen Inc. (NASDAQ: AMGN) were trading normally following... Read the Full Story |
|
From Our PartnersLet MarketBeat All Access be your virtual research assistant that keeps track of your stocks and the market for you. Now just $9.97 per month. | | | | Learn More Here |
|
Stocks | | | A choppy day of trading on Wall Street ended Friday with slight gains for stocks, as the market notched its second straight winning week.The market got a boost early on from a closely watched government report that showed U.S. job growth increased at a healthy, but more moderate pace last month. The... Read the Full Story |
|
Markets | | | America's employers added 187,000 jobs in August, evidence of a slowing but still-resilient labor market despite the high interest rates the Federal Reserve has imposed. Last month's job growth marked an increase from July's revised gain of 157,000 but still pointed to a moderating pace of hiring co... Read the Full Story |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | | | Go HERE to Reveal Which Stock These Are |
|
Markets | | |
One of the most astonishing and widely discussed subjects in individual stocks revolves around the unpredictability and volatility of a Vietnamese electric vehicle manufacturer.
VinFast Auto Ltd. (NASDAQ: VFS) plunged into the public market through a SPAC IPO at the beginning of the month. M... Read the Full Story |
|
Markets | | | The average long-term U.S. mortgage rate declined this week after climbing five consecutive weeks to a more than 20-year high, a modest relief for would-be homebuyers challenged by rising home prices and a thin inventory of homes on the market Read the Full Story |
|
Markets | | | Oprah Winfrey and Dwayne Johnson have committed $10 million to make direct payments to people on Maui who are unable to return to their homes because of the wildfires, through a new fund they announced Thursday.The People's Fund of Maui will give $1,200 a month to adults who are not able to return t... Read the Full Story |
|
Markets | | | India’s economy registered impressive growth of 7.8% in the first quarter of the current financial year (April-June), attributed to good performance by the agriculture and financial sectors, according to official data released on Thursday.The World Bank says India is one of the fastest-growing econo... Read the Full Story |
|
Markets | | |
The market advanced following the August PCE price index report, but investors and traders should not discount the news. The PCE index remains cool relative to the peaks of the inflation scare, but there are signs that the cooling is over.
Inflation may accelerate again; the evidence c... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
